| Accession |
PRJCA016737 |
| Title |
To investigate the safety, tolerability, pharmacokinetics and efficacy of SHR2554 in patients with relapsed/refractory mature lymphocytic neoplasms |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
The safety, tolerability, pharmacokinetics and efficacy of SHR2554 in patients with relapsed/refractory mature lymphocytic neoplasms were evaluated |
| Sample scope |
Multiisolate |
| Release date |
2023-05-05 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-05-05 |
